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Introduction. We examined the murine hepatectomy model of liver regeneration (LR) in the setting of neoadjuvant chemotherapy.
Methods. C57BL/6 mice were randomized to receive neoadjuvant intraperitoneal (IP) injections of a control, oxaliplatin
(15mg/kg), or irinotecan (100mg/Kg or 250mg/Kg) solution. Hepatectomy (70%) was performed 14 days after the ﬁnal IP
treatment. Animals were sacriﬁced at postoperative day (D) 0, 1, 2, 3, and 7. Liver remnants and serum were collected for analysis.
T-tests for independent samples were used for statistical comparisons. Results. For oxaliplatin, percent LR did not diﬀer at D1
or D2 but was signiﬁcantly less at D3 (89.0% versus 70.0%, P = 0.048) with no diﬀerence on D7 (P = 0.21). Irinotecan-treated
miceatbothdoselevels(100mg/Kgand250mg/Kg)showednosigniﬁcantdiﬀerencesinLR.BrdUincorporationwassigniﬁcantly
decreased in oxaliplatin-treated animals (D1,2,3). Conclusions. Neoadjuvant oxaliplatin but not irinotecan impairs early LR in a
posthepatectomy murine model which correlates with decreased DNA synthesis.
1.Introduction
2010 an estimated 142,570 people developed colorectal
cancer (CRC) with an estimated 51,370 people dying of the
disease [1]. Synchronous liver metastases are found in 20%
of patients, and more than half of those diagnosed with
CRC will go on to develop metachronous liver metastases
[2, 3]. Liver only or liver-predominant disease aﬀects
20–35% of patients, aﬀording those with resectable lesions
the possibility of long-term survival. In selected cases with
R0 resection, 10-year overall survival has been reported
in the literature to range from 17–25% [4, 5]. In addition
to its adjuvant use in Stage 3 colon cancer and following
hepatic resection, chemotherapy has the potential to
convert borderline or unresectable liver disease to resectable
disease by reducing the size of the tumor to an amenable
dimension. Furthermore, neoadjuvant chemotherapy has
been advocated as a test for aggressive tumor biology [6–8].
Timing and appropriateness of chemotherapy, however, is
debated, and there are concerns regarding worse outcomes
in heavily treated patients [9]. In this regard, steatohepatitis,
steatosis, and sinusoidal injury have been linked to the use
of irinotecan, ﬂuoropyrimidines and oxaliplatin [10].
Animal models for the study of posthepatectomy liver
r e g e n e r a t i o na r ew e l ld e s c r i b e d[ 11] .T h e s em o d e l sh a v ey e t
to be applied to the study of commonly used agents for CRC.
Given ﬁrst-line use of oxaliplatin and irinotecan for stage IV
CRC, these agents were chosen for investigation. We hypoth-
esized that posthepatectomy liver regeneration is impaired
by oxaliplatin and/or irinotecan administration and that this
impairment can be demonstrated in a mouse model.
2.MaterialsandMethods
2.1. Animal Maintenance and Treatments. Eight-week-old
C57BL/6 male mice, weighing between 23–25 grams, were2 International Journal of Hepatology
obtained from commercial sources (Taconic Farms, Hudson,
NY). The animals were housed under standard 12-hour
light/12-hour dark conditions with standard feed and water
ad libitum. After a minimum of 48 hours acclimation,
animals were randomized to receive either oxaliplatin
(15mg/Kg), irinotecan (100 mg/kg or 250 mg/kg) or control
solution (dextrose 5% water) by intraperitoneal injection.
Animal tolerance of chemotherapy was closely monitored,
and posthepatectomy animals were evaluated daily. Animal
handling, drug administration, monitoring, and survival
surgery protocols were approved by the City of Hope,
Research Animal Care Committee.
2.2. Chemotherapy. Oxaliplatin and irinotecan were ob-
tained through the City of Hope, Investigational Drug Ser-
vices and diluted in non-chloride-containing solution (dex-
trose 5% water) to deliver the determined dose in an ap-
proximate volume of 100mcL. Dose regimens were based
on data from in vivo activity in previously described colon
cancer tumor models in mice [12, 13]. Oxaliplatin 15mg/Kg
wasadministeredIP ×1dose.Irinotecanwasadministeredat
two dose levels as follows: regimen A, 100mg/Kg, IP divided
in 2 weekly doses and regimen B, 250mg/Kg IP divided in
3 weekly doses (75mg/Kg, 75mg/Kg, 100mg/Kg). Fourteen
days after the last control or chemotherapy injection, a 70%
hepatectomy was performed. Despite using well-established
dosing schedule [12] in a dedicated vivarium with skilled
personnel, 19 of 32 animals died from the initial treatment
with oxaliplatin. There was no mortality in the irinotecan
group. All surviving animals were included in the surgical
portion of the experiment.
2.3. Animal Surgery. The left and median lobes were resected
with preservation of the gallbladder for 70% hepatectomy.
Brieﬂy, tribromoethanol (Avertin) anesthetic was adminis-
tered IP (250mg/Kg). After sterile prep a subxiphoid tran-
sverse incision was created and the median and left liver
lobes were exteriorized. The lobes were encircled with silk
ligature, their vascular pedicles tied at the base and the
lobes resected. Care was taken to spare the gallbladder
and associated bile ducts. Closure was accomplished with
autoclips. Buprenorphine was administered (0.5mg/Kg sub-
cutaneously) upon awakening. At postoperative days 0,
1, 2, 3, and 7, remnant right and caudate lobes were har-
vested, and blood was collected from the retroorbital
sinus concomitant with animal sacriﬁce. In the oxaliplatin
experimented cohort, there were 3 perioperative deaths (2
oxaliplatin treated, 1 control). There was no mortality in the
irinotecan cohort.
2.4. Percent Liver Regeneration by Mass. Percent liver re-
growth was calculated by the following formula: (Mass of
regenerating liver remnant in grams) ÷ (Mass of resected
liver lobes in grams)/(0.7) × 100.
2.5. Liver Histology and Bromodeoxyuridine (BrdU) Incor-
poration. In vivo BrdU staining was accomplished by intra-
peritoneal injection of BrdU (100mg/Kg) 2 hours prior
0
20
40
60
80
100
120
1234567
(day)
R
e
g
r
o
w
t
h
(
o
r
i
g
i
n
a
l
m
a
s
s
%
)
Control
Oxaliplatin
∗
∗
∗P = 0.0485
Figure 1: Liver regeneration by percent regrowth, oxaliplatin
15mg/Kg versus control, diﬀers signiﬁcantly at day 3.
to sacriﬁce. Uniform samples of hepatic parenchyma were
removed and ﬁxed in 4% formaldehyde solution, embedded
in paraﬃn, sectioned at 5 micrometers, and stained with
hematoxylin and eosin. BrdU immunohistochemical stain-
ing was performed using a commercially available kit
(Roche). The number of positively stained nuclei was count-
ed in 3 randomly selected high-power ﬁelds per sample, one
sample from at least 2mice per time point and arm.
2.6. ALT Analysis. Under anesthesia prior to sacriﬁce,
approximately 500mcL of blood was drawn from the retro-
orbital sinus and placed in serum separator tubes (Falcon).
Collected serum was then analyzed for ALT after 10-fold
dilution in 7% bovine serum albumin.
2.7. Statistical Analysis. Statistical comparisons were per-
formed using t-tests for independent samples.
3. Results
3.1. Oxaliplatin. 22 animals underwent 70% hepatectomy in
the oxaliplatin versus control study, 9 animals in the control
arm, and 13 in the oxaliplatin arm. Animal weights of the
survivors were similar to those of the control group at the
time of hepatectomy. There were 3 perioperative deaths; 1
in the control arm and 2 in the oxaliplatin arm which were
technical in nature (pneumothorax, excessive manipulation
of lobes on extraction, and hemorrhage).
Percent liver regrowth (Table 1 and Figure 1)a td a y1
following hepatectomy did not diﬀer between oxaliplatin-
treated and control mice (56.1% versus 52.5%, resp., P =
0.312). Data collected on day 2 suggests less regrowth in the
oxaliplatin-treated arm (57.6% versus 73.0%, P = 0.154);
however this was not statistically signiﬁcant. Regeneration
was signiﬁcantly less in the treatment arm at day 3 (70.0%International Journal of Hepatology 3
Table 1: Liver regeneration after oxaliplatin treatment, percent regrowth by mass, days 1, 2, 3, and 7.
Day Regrowth control Regrowth oxaliplatin Independent T-test
Day 1 56.1% (N = 2) 52.5% (N = 3) P = 0.312
Day 2 73.0% (N = 2) 57.6% (N = 3) P = 0.154
Day 3 89.0% (N = 2) 70.0% (N = 3) P = 0.048
Day 7 99.0% (N = 2) 89.8% (N = 2) P = 0.214
N, number of animals per group.
versus 89.0%, P = 0.048). By 7 days following hepatectomy,
delayed LR in the oxaliplatin-treated arm was no longer
found to be statically signiﬁcant (89.8% versus 99.0%, P =
0.214).
Hepatocyte injury was assessed by measurement of ALT
levels. ALT levels peaked at posthepatectomy day 1 and
normalize by day 3. ALT levels in oxaliplatin-treated animals
were not found to be statistically diﬀerent than controls
throughout the study (Figure 5).
BrdU incorporation was used to determine if oxaliplatin
impairs DNA synthesis (cellular division), thus contributing
to impaired liver regrowth (Figure 3). DNA synthesis was
signiﬁcantly higher in the control arm at all three measured
timepoints. Oxaliplatin-treated animals showed signiﬁcantly
less incorporation consistent with reduced DNA synthesis.
3.2. Irinotecan. In the irinotecan experiments no animals
experienced chemotherapy-related mortality. Weights were
similar between groups at the time of hepatectomy. Neither
dose level, group A (100mg/Kg, N = 15; control N = 8)
nor group B (250mg/Kg, N = 17; control N = 5) showed
signiﬁcant impairment in liver regrowth by mass compared
with respective controls (Figure 2). Similar to the oxaliplatin
group, irinotecan-treated animals showed peak ALT levels
at day 1 with return to baseline between days 3–7 (data
not shown). In contrast to the oxaliplatin results, BRDU
incorporation in irinotecan-treated animals was similar or
increased compared to controls (Figure 4).
3.3. Histology. Histologic examination of regenerating liver
specimensshowednoevidenceofhepaticsinusoidalobstruc-
tion in oxaliplatin-or-irinotecan treated animals. Mild bal-
looning changes due to increased cytoplasmic water were
seen in both treated and untreated groups. In the oxaliplatin
arm, mild portal inﬂammation with necrosis near the portal
triads and microvesicular steatosis were seen in two animals,
one at posthepatectomy day 2 and one at day 3.
4. Discussion
The liver’s remarkable ability to restore a functionally ade-
quateportionofitspreviousvolumefollowingsurgicalresec-
tion is tightly regulated by mechanisms that include bile acid
interactions with the FXR nuclear receptor and several other
complex mechanisms [11, 14]. The mouse liver regeneration
m o d e li sw e l ld e s c r i b e da n dh i g h l yr e p r o d u c i b l ei nt h i s
posthepatectomy setting. The diﬀerences in regeneration are
demonstrated at early timepoints, namely, days 2 and 3 after
hepatectomy [11]. We chose to apply this model to the study
of liver regeneration after treatment with commonly used
modern chemotherapeutic agents for CRC. The oxaliplatin
dose was selected based on established, species-speciﬁc doses
from the research literature [12]. An unexpected toxicity
(mortality) was observed in this experiment. The animal
deaths aﬀected the group sizes, but only impacted the
planned experimental animal numbers (approved by the
Research Animal Care Committee) that would be required
to achieve deﬁnitive statistical results in one cohort.
We discovered that oxaliplatin-treated animals showed
signiﬁcantly reduced regrowth on the third posthepatectomy
day. This ﬁnding has not been previously described in a
preclinical model and may, in part, be due to the mechanism
of oxaliplatin cytotoxicity. Oxaliplatin is a third-generation
platinum derivative that acts at the level of DNA by forming
bulky DNA adducts [15]. Most commonly, intrastrand links
between guanine and adenine are formed by the platinum
moiety. DNA synthesis is impaired by these adducts which
in turn leads to strand breaks and subsequent apoptosis.
Oxaliplatin’s mechanism of action is consistent with the
marked decrease in DNA synthesis demonstrated by the
decrease in BrdU staining in these experiments. BrdU
staining was more sensitive than percent regrowth by weight.
Analysis of oxaliplatin’s impact on BrdU staining were
demonstrated with signiﬁcant diﬀerences as early as day 1
following hepatectomy with signiﬁcant impairment in DNA
synthesis continuing through day 3. These data combined
with the absence of direct hepatic damage, as evidenced by
nonsigniﬁcant diﬀerences in ALT, suggest oxaliplatin blunts
LR by inhibiting cell division in the early postoperative
period. However, this eﬀect appears to be lost by 7 days
postoperatively as physiologic mechanisms to restore
appropriate liver function normalize liver size by this time.
Despite the consistency (growth and DNA synthetic activity)
of these data, the small number of experimental animals
requires they be viewed as exploratory, not deﬁnitive.
The experimental model is well established, and the BrdU
incorporation is a sensitive measure of DNA synthesis.
The current literature contains variable conclusions on the
impact of chemotherapy on liver regeneration. In part,
t h i si sd u et od i ﬀerences in experimental modeling (e.g.,
number of chemotherapy injections, use of Ki-67, and single
time-point analysis). The current series of experiments
provides sequential time point evaluation at 0, 1, 2, 3, and 7
days in an attempt to mimic the immediate, early, and longer
phases of hepatic regeneration in the human. This sequential
reporting is unique in investigations of this type. This topic
area remains controversial, and additional experiments with4 International Journal of Hepatology
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Figure 2: Liver regeneration by percent regrowth does not dif-
fer after irinotecan treatment at cumulative 100mg/Kg (a) and
250mg/Kg (b) dose levels.
a consistent experimental model will be the most deﬁnitive
way to answer the controversies and variability in results.
Irinotecan-treated animals did not show diﬀerences in
liver regrowth despite treatment at previously documented
pharmacologically active doses [16, 17]. BrdU incorporation
assayscorroboratetheseﬁndingswithnodecreasebutrather,
a nonstatistically signiﬁcant increase in DNA synthesis.
Increased DNA synthesis with irinotecan treatment may be
relatedtothedrug’smechanismofaction.Irinotecaninhibits
topoisomerase I, stabilizes single-strand breaks and results in
double-strand breakage though interaction at the replication
fork [18]. Our results suggest that the structure and coiling
of DNA is altered by irinotecan without direct eﬀect on the
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Figure 3: BrdU incorporation is signiﬁcantly less in oxaliplatin-
(15mg/kg) treated animals at days 1, 2, and 3.
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Figure 4: BrdU incorporation is increased in irinotecan-
(100mg/kg) treated animals.
cells ability to synthesize DNA and thus incorporate BrdU.
Despitethesomewhatcounterintuitivenatureofthisﬁnding,
a higher proportion of cells in S-phase after irinotecan
treatment has been described in animal and clinical settings
[19].
High toxicity was seen in the animals receiving oxali-
platin. This occurred despite the use of previously reported
doses [20]. In our experiments, although the toxicity was
high during the administration of oxaliplatin, the surviving
animals were fully recovered prior to hepatectomy with no
diﬀerence in animal weight or appearance in the oxaliplatin-
treated animals when compared to irinotecan-treated ani-
mals. This argues that diﬀerences in regrowth were liverInternational Journal of Hepatology 5
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Figure 5: Representative plot of ALT levels showing a peak at day 1
with normalization between day 3 and 7.
speciﬁc and not a byproduct of other factors such as a weak-
ened state or poor nutrition.
Recently, clinical studies have raised concerns regarding
the signiﬁcant hepatotoxicity of chemotherapeutic agents
for CRC [21]. Oxaliplatin is implicated in the “blue
liver” syndrome from hepatic sinusoidal obstruction, and
worse posthepatectomy outcome is reported in association
with chemotherapy-related steatohepatitis primarily with
irinotecan [22, 23]. Histologic examination of the liver in 2
animals showed microvesicular steatosis and mild periportal
inﬂammation. However, this was an uncommon ﬁnding.
The diﬀerences seen in regeneration and DNA synthesis,
therefore, likely reﬂect changes not yet evident on H&E, but
in part detectable with special staining techniques such as
BrdU immunohistochemistry.
Clinical guidelines for hepatectomy recommend more
conservative volumes of liver resection in chemotherapy-
treated patients with a goal future liver remnant of 30%,
rather than 20% [16, 24]. Given the adverse eﬀects of
chemotherapy on the liver, our goal was to establish an ani-
mal model to study these interactions. We have shown early
impairment of regenerative ability in oxaliplatin-treated
animals. These ﬁndings are corroborated by decreased DNA
synthesis. These data suggest that early in the patient’s
postoperative course, when the risk for liver failure is higher,
regenerative mechanisms may be impaired. Future studies
with this model will aim at abrogating these eﬀects.
5. Conclusion
The mouse 70% hepatectomy model provides a useful tool
forstudyingtheeﬀectsofchemotherapyonposthepatectomy
liver regeneration. We demonstrate that oxaliplatin impairs
early liver regeneration in a posthepatectomy model and
that this reduced regrowth correlates with decreased DNA
synthesis.Conversely,irinotecandidnotimpairregeneration
or DNA synthesis.
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